Key points are not available for this paper at this time.
The initial encouraging activity of ruxolitinib in myelofibrosis appears to need some caveats when long-term efficacy is examined. The control of splenomegaly may not be durable, and the likelihood of leukemic progression or death is not dramatically lowered.
Tefferi et al. (Wed,) studied this question.